Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

被引：0

作者：

Montalban-Bravo, Guillermo ^{[1
]}

Short, Nicholas J. ^{[1
]}

Chien, Kelly S. ^{[1
]}

Valero, Yesid Alvarado ^{[1
]}

Daver, Naval ^{[1
]}

Borthakur, Gautam ^{[1
]}

Swaminathan, Mahesh ^{[1
]}

Maiti, Abhishek ^{[2
]}

Hammond, Danielle E. ^{[1
]}

Nogueras-Gonzalez, Graciela ^{[3
]}

Huang, Xuelin ^{[3
]}

Schneider, Heather ^{[4
]}

Shelly, Kristen ^{[4
]}

Kadia, Tapan M. ^{[1
]}

Kantarjian, Hagop M. ^{[4
]}

Garcia-Manero, Guillermo ^{[5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Biostat, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Kadia, Tapan M.
Reville, Patrick K.
Wang, Xuemei
Rausch, Caitlin R.
Borthakur, Gautam
Pemmaraju, Naveen
Daver, Naval G. G.
DiNardo, Courtney D. D.
Sasaki, Koji
Issa, Ghayas C. C.
Ohanian, Maro
Montalban-Bravo, Guillermo
Short, Nicholas J. J.
Jain, Nitin
Ferrajoli, Alessandra
Bhalla, Kapil N. N.
Jabbour, Elias
Takahashi, Koichi
Malla, Rashmi
Quagliato, Kelly
Kanagal-Shamanna, Rashmi
Popat, Uday R. R.
Andreeff, Michael
Garcia-Manero, Guillermo
Konopleva, Marina Y. Y.
Ravandi, Farhad
Kantarjian, Hagop M. M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3848 - +
[2] Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
Pullarkat, Vinod
Pratz, Keith W.
Doehner, Hartmut
Recher, Christian
Thirman, Michael J.
Dinardo, Courtney D.
Fenaux, Pierre
Schuh, Andre C.
Wei, Andrew H.
Pigneux, Arnaud
Jang, Jun-Ho
Juliusson, Gunnar
Miyazaki, Yasushi
Selleslag, Dominik
Arellano, Martha L.
Liu, Chenglong
Ridgeway, Jean A.
Potluri, Jalaja
Schuler, Jovita
Konopleva, Marina
BLOOD CANCER JOURNAL, 2025, 15 (01):
[3] Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study
Li, Yanyan
Zhou, Haixia
Wan, Chaoling
Xu, Mingzhu
Qian, Chongsheng
Zhang, Tongtong
Dai, Haiping
Sun, AiNing
Wu, Depei
Xue, Shengli
BLOOD, 2022, 140 : 3212 - 3213
[4] Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Montalban-Bravo, Guillermo
Bose, Prithviraj
Alvarado, Yesid
Daver, Naval Guastad
Ravandi, Farhad
Borthakur, Gautam
Takahashi, Koichi
Andreeff, Michael
Cortes, Jorge E.
Dinardo, Courtney Denton
Jabbour, Elias
Kadia, Tapan M.
Kornblau, Steven
Ohanian, Maro
Huang, Xuelin
Nogueras-Gonzalez, Graciela M.
Bodden, Kristy
Pierce, Sherry
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial
Bataller, Alex
Bazinet, Alexandre
Borthakur, Gautam
Short, Nicholas J.
Jabbour, Elias
Takahashi, Koichi
Daver, Naval
Issa, Ghayas C.
DiNardo, Courtney D.
Pemmaraju, Naveen
Jain, Nitin
Montalban-Bravo, Guillermo
Wierda, William G.
Garcia-Manero, Guillermo
Ravandi, Farhad
Kantarjian, Hagop M.
Kadia, Tapan M.
BLOOD, 2023, 142
[6] Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study
Bataller, Alex
Sasaki, Koji
Urrutia, Samuel
Montalban-Bravo, Guillermo
Bazinet, Alexandre
Chien, Kelly
Hammond, Danielle
Bouligny, Ian M.
Swaminathan, Mahesh
Issa, Ghayas
Short, Nicholas
Daver, Naval
DiNardo, Courtney D.
Kadia, Tapan
Jabbour, Elias
Ravandi, Farhad
Roboz, Gail J.
Savona, Michael
Griffiths, Elizabeth A.
McCloskey, James
Odenike, Olatoyosi
Oganesian, Aram
Keer, Harold N.
Azab, Mohammad
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD CANCER JOURNAL, 2025, 15 (01):
[7] Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose- escalation, dose-expansion, phase 1-2 study
Bazinet, Alexandre
Darbaniyan, Faezeh
Jabbour, Elias
Montalban-Bravo, Guillermo
Ohanian, Maro
Chien, Kelly
Kadia, Tapan
Takahashi, Koichi
Masarova, Lucia
Short, Nicholas
Alvarado, Yesid
Yilmaz, Musa
Ravandi, Farhad
Andreeff, Michael
Kanagal-Shamanna, Rashmi
Ganan-Gomez, Irene
Colla, Simona
Qiao, Wei
Huang, Xuelin
McCue, Deborah
Mirabella, Bailey
Kantarjian, Hagop
Garcia-Manero, Guillermo
LANCET HAEMATOLOGY, 2022, 9 (10): : E756 - E765
[8] PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES
Zeidan, A. M.
Garcia, J.
Fenaux, P.
Platzbecker, U.
Miyazaki, Y.
Xiao, Z.
Zhou, Y.
Naqvi, K.
Kye, S.
Manero, G. Garcia
LEUKEMIA RESEARCH, 2021, 108 : S47 - S47
[9] Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Morita, Kiyomi
Naqvi, Kiran
Montalban, Guillermo
Thompson, Philip A.
Takahashi, Koichi
Alvarado, Yesid
Jabbour, Elias
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[10] Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
Yan-Yan Li
Shuai-Shuai Ge
Yuan-Hong Huang
Ming-Zhu Xu
Chao-Ling Wan
Kai-Wen Tan
Tao Tao
Hai-Xia Zhou
Sheng-Li Xue
Hai-Ping Dai
Blood Cancer Journal, 14

← 1 2 3 4 5 →